Ozone Pharmaceuticals' RAS net profit for 3 months of 2025 amounted to ₽0.429 billion, down 2.8 times from ₽1.2 billion in the previous year. Revenue fell 41.5% to ₽0.708 billion against ₽1.21 billion a year earlier.